New 'Cicada' COVID-19 Variant Emerges

A heavily mutated descendant of Omicron has surfaced in more than two dozen countries, raising fresh questions about immune evasion, vaccine durability, and what "normal" viral evolution looks like in a post-pandemic world.

The Basics: What Is BA.3.2?

The variant formally designated BA.3.2 belongs to the Omicron lineage of SARS-CoV-2. It descends from BA.3, an Omicron subvariant that first emerged in 2022 but never gained a foothold against more competitive siblings like BA.5 [1]. Researchers named it "Cicada" in December 2025, a nod to the insect that spends years underground before emerging en masse—a parallel to the variant's own trajectory of circulating at low levels before suddenly expanding [2].

The first known BA.3.2 sample was collected from a five-year-old child in South Africa on November 22, 2024 [3]. Molecular clock estimates suggest the lineage diverged from its parent sometime between December 2023 and July 2024, meaning it spent months evolving in relative obscurity before genomic surveillance flagged it [2].

The Mutation Profile

BA.3.2 carries approximately 70 to 75 substitutions and deletions in its spike protein relative to the JN.1 and LP.8.1 lineages that have dominated global circulation since 2024 [3][4]. By comparison, JN.1 itself carried roughly 35 spike mutations, and LP.8.1 about 40 [4]. The gap between BA.3.2 and the current vaccine target strain is larger than the gap between JN.1 and XBB.1.5—the two strains that prompted the last vaccine reformulation [3].

Source: CDC MMWR

Data as of Mar 12, 2026CSV

Specifically, the CDC's Morbidity and Mortality Weekly Report documented 20 receptor-binding domain (RBD) differences—the region of the spike protein that directly attaches to ACE2 receptors on human cells—and 35 N-terminal domain (NTD) differences [3]. The NTD is a key target for certain classes of neutralizing antibodies, so extensive changes there raise concern about immune escape. BA.3.2 also features deletions at spike sites 136–147 and 243–244, plus a four-amino acid insertion after site 214 [3].

Not all of these mutations are straightforward bad news. Two laboratory studies found that BA.3.2 variants showed "substantially reduced angiotensin-converting enzyme 2 (ACE2) binding and lung cell entry" [3]. ACE2 is the cellular receptor SARS-CoV-2 uses to infect cells, so weaker binding could limit the variant's ability to rapidly outcompete rivals or cause severe lower respiratory disease—though this remains preliminary.

Where Is Cicada Spreading?

As of the CDC's March 12, 2026 update, BA.3.2 has been detected in at least 23 countries [3]. The variant has established its strongest foothold in Northern Europe, accounting for approximately 30% of sequenced COVID-19 cases in Denmark, Germany, and the Netherlands [5][6]. The United Kingdom and Japan have also reported sustained detection [1].

Source: CDC MMWR / GISAID

Data as of Mar 12, 2026CSV

In the United States, the picture has shifted rapidly. The first domestic detection came from a San Francisco traveler returning from the Netherlands on June 27, 2025 [3]. By November 2025, BA.3.2 appeared in Rhode Island wastewater samples, and the first U.S. clinical patient case was confirmed on January 5, 2026 [3]. As of the week ending March 21, 2026, BA.3.2 accounted for roughly 11% of wastewater detections nationally, up from 0.55% just weeks earlier in mid-February [7][3].

Source: CDC Genomic Surveillance

Data as of Mar 21, 2026CSV

The CDC's multimodal surveillance approach—combining GISAID genomic databases, the Traveler-Based Genomic Surveillance program, and the National Wastewater Surveillance System across 150 sites—has tracked detections across 29 states and Puerto Rico [3]. Among sequenced clinical specimens, BA.3.2 represented 0.55% of 2,579 sequences as of March 12, the most recent data available. The wastewater signal, however, runs substantially higher, suggesting undercounting in clinical sequencing [3].

Severity: What the Clinical Data Shows

The question that matters most to individuals—does Cicada make people sicker?—currently has a reassuring, if incomplete, answer.

"The early data would indicate that it is not more severe, or it doesn't have any distinctive clinical presentations," said Dr. William Schaffner, an infectious disease specialist at Vanderbilt University Medical Center [5][6]. Symptoms reported in BA.3.2 cases are consistent with those from other circulating variants: cough, congestion, fatigue, sore throat, and fever [4][8].

The CDC's MMWR report documented that among the earliest U.S. clinical detections, two were hospitalized older adult patients with comorbidities and one was a young child who received outpatient care. All three survived [3]. This is too small a sample to draw statistical conclusions, but the pattern is consistent with data from countries where BA.3.2 has circulated longer.

Crucially, unlike earlier concerning variants such as Delta, BA.3.2 has not been associated with increased rates of hospitalization or death in countries like Denmark and Germany where it has achieved high prevalence [5][8]. The WHO stated in its assessment that "BA.3.2 has not shown a sustained growth advantage over any other co-circulating variant" [1].

The reduced ACE2 binding observed in laboratory studies may partly explain this. If the variant has traded some cellular entry efficiency for immune evasion capability, it could spread among vaccinated and previously infected populations while causing less severe lower airway disease [3].

Vaccine Protection: Diminished but Not Gone

The 2025–2026 COVID-19 vaccines target the LP.8.1 lineage, a JN.1 descendant [3]. With BA.3.2 carrying roughly 75 spike mutations compared to LP.8.1, laboratory neutralization studies have yielded expected results: reduced antibody effectiveness.

The CDC reported that the current adapted mRNA vaccine "demonstrates protection against currently predominant JN.1 strains but had the lowest antibody neutralization against BA.3.2" [3]. Dr. Donald Milton, a respiratory disease expert at the University of Maryland, characterized the situation plainly: "Vaccines may not work well against 'cicada' infection, but will still probably protect against severe illness" [5][6].

This distinction—between preventing infection and preventing hospitalization or death—has been a consistent feature of COVID-19 vaccine performance since Omicron first appeared in late 2021. Neutralizing antibody levels measured in lab dishes correlate imperfectly with real-world protection, which also depends on T-cell responses and immune memory that are harder to measure but more durable across variant changes.

Dr. Robert H. Hopkins of the National Foundation for Infectious Diseases noted that BA.3.2 "is currently a minority strain, based on the most recent data available from CDC" and emphasized that the current vaccine formulation remains the recommended protection through fall 2026 [5]. If BA.3.2 continues gaining ground, the fall 2026 vaccine formulation may be updated to include coverage [6].

The WHO has said current vaccines "are expected to continue providing protection against severe disease" [9].

Who Is Most Vulnerable?

The populations at elevated risk from BA.3.2 are the same groups that have faced disproportionate danger throughout the pandemic: adults over 65, immunocompromised individuals, and people with chronic conditions including lung disease, diabetes, cardiovascular disease, and obesity [4][10].

COVID-19 continues to kill approximately 100,000 Americans annually, with older adults and immunocompromised patients bearing a disproportionate share of that burden [10]. Long COVID occurs in approximately 3 out of every 100 cases, though this rate has declined as the virus has evolved and population immunity has built up [4].

What makes BA.3.2 a particular concern for these groups is the degree of spike protein divergence from the strains their immune systems have most recently encountered. Dr. Schaffner and other clinicians describe BA.3.2 as an "almost complete stranger" to U.S. immune systems [4]. For healthy individuals with robust and recent immunity, this likely means a higher chance of symptomatic infection but low risk of severe outcomes. For the immunocompromised—whose immune systems may not mount strong responses even to well-matched vaccines—the calculus is less favorable.

No population-level hospitalization breakdowns specific to BA.3.2 in vulnerable groups have been published yet. The CDC has indicated it is monitoring outcomes closely but has not issued any new clinical guidance specific to the variant [3].

Why Now? Evolutionary Context

BA.3.2's emergence roughly six years into the pandemic reflects well-established patterns of RNA virus evolution rather than a novel or unexpected event.

SARS-CoV-2 evolves through two primary mechanisms. The first is gradual antigenic drift—the accumulation of point mutations under selective pressure from population immunity, similar to how influenza evolves seasonally. The second, more relevant to BA.3.2, is saltatory evolution: the sudden appearance of a highly divergent lineage, likely after prolonged replication in a single immunocompromised host whose immune system applies partial but sustained selective pressure [2][3].

BA.3.2's mutation profile—dozens of changes clustered in antigenic sites—is consistent with this chronic infection hypothesis. The variant's parent lineage, BA.3, was a minor player in the Omicron wave of 2022. For it to re-emerge years later with 53 additional spike mutations relative to ancestral BA.3 suggests extended evolution in an environment with partial immune pressure [2].

This pattern has precedent. The original Omicron variant (BA.1) itself appeared suddenly in late 2021 with an unprecedented number of mutations, likely after evolving in a chronically infected individual [2]. Alpha and several other variants of concern showed similar signatures.

Waning population immunity also plays a role. As time since last vaccination or infection increases, neutralizing antibody levels decline, creating ecological space for divergent variants that would otherwise be suppressed. The combination of waning immunity, reduced vaccine uptake in many countries, and the ongoing reality of immunocompromised individuals serving as evolutionary reservoirs means that novel variants will continue to emerge for the foreseeable future [10].

The Surveillance Debate

BA.3.2 has reignited a recurring argument: does intensive COVID variant monitoring serve public health, or does it perpetuate anxiety about a virus that is, for most people, now manageable?

Critics note that influenza genomic surveillance identifies new variants every season without triggering public alarm or media cycles. The argument, articulated forcefully in some conservative media outlets, frames variant monitoring as a relic of pandemic-era thinking. "The panic over variants has always been absurd, and continues to be," wrote one commentator, characterizing the pattern as predictable for "a highly transmissible respiratory virus that will continually evolve and change" [11].

There is a kernel of truth in this critique. Not every new variant warrants a public response, and media coverage that emphasizes mutation counts without contextualizing severity can mislead. The fact that BA.3.2 carries 75 spike mutations sounds alarming in isolation; the fact that it has not caused increased hospitalizations in countries where it has been circulating for months is the more operationally relevant data point.

On the other side, public health researchers argue that genomic surveillance is precisely what allows health systems to distinguish routine evolution from genuine threats. The CDC's MMWR report on BA.3.2 exemplifies this: it documents the variant's genetic profile, tracks its spread, reports preliminary clinical outcomes, and measures vaccine neutralization—all of which inform decisions about vaccine reformulation, clinical guidance, and resource allocation [3].

The practical question is what severity thresholds should trigger public health action. The WHO's tiered classification system—variants under monitoring, variants of interest, variants of concern—attempts to answer this. BA.3.2 is currently classified as a "variant under monitoring," the lowest tier, reflecting its genetic divergence but lack of evidence for increased severity or transmissibility advantage [2][12]. If clinical data showed rising hospitalization rates, the classification would change and trigger more aggressive response measures.

Dr. Schaffner offered a middle-ground perspective: the variant warrants attention from public health systems and continued surveillance, but "is not a reason for healthy individuals to panic" [6]. Annual COVID-19 vaccination, similar to the flu shot model, remains the recommended baseline for most adults [5].

What Comes Next

The trajectory of BA.3.2 remains uncertain. Unlike previous variants of concern—Alpha, Delta, original Omicron—that rapidly swept to dominance, BA.3.2 has cocirculated with JN.1 descendants without displacing them, reaching prevalences of 10% to 40% in several European countries rather than 90%+ [3]. Its reduced ACE2 binding efficiency may impose a ceiling on its competitive fitness.

Three scenarios are plausible. BA.3.2 could plateau as a minority lineage, contributing to ongoing viral diversity without dominating. It could gradually increase its share, particularly as population immunity to JN.1 descendants wanes. Or a sublineage—the CDC has identified two major branches, BA.3.2.1 and BA.3.2.2, with designated sublineages RE.1.1 and RE.2.2 driving most of the variant's growth—could acquire additional mutations that improve transmissibility [2][3].

The fall 2026 vaccine advisory process, which typically convenes in June, will weigh whether BA.3.2's prevalence and immune evasion profile justify inclusion in the next formulation [6]. At-home COVID-19 tests remain effective against BA.3.2, as they target conserved viral proteins that mutate slowly [5][6].

For now, the standard recommendations apply: stay current on vaccinations, test when symptomatic, and seek treatment early if you are in a high-risk group. The Cicada variant is a reminder that SARS-CoV-2 continues to evolve—but six years of accumulated immunity, improved treatments, and better surveillance mean the consequences of that evolution are substantially different from what they were in 2020.

Source: OpenAlex

Data as of Jan 1, 2026CSV